Premium
Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid
Author(s) -
Honda Yohji,
Aikata Hiroshi,
Honda Fumi,
Nakano Norihito,
Nakamura Yuki,
Hatooka Masahiro,
Morio Kei,
Kobayashi Tomoki,
Fukuhara Takayuki,
Nagaoki Yuko,
Kawaoka Tomokazu,
Hiramatsu Akira,
Imamura Michio,
Kawakami Yoshiiku,
Chayama Kazuaki
Publication year - 2017
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12844
Subject(s) - medicine , hepatocellular carcinoma , zoledronic acid , multivariate analysis , stage (stratigraphy) , retrospective cohort study , gastroenterology , oncology , cohort , bone remodeling , n terminal telopeptide , receiver operating characteristic , paleontology , biochemistry , chemistry , alkaline phosphatase , osteocalcin , biology , enzyme
Aims We retrospectively analyzed the clinical outcome and prognostic parameters in patients with hepatocellular carcinoma (HCC) and bone metastases who had received treatment with zoledronic acid (ZOL). Methods Ninety‐nine HCC patients with bone metastases who had been treated with ZOL were enrolled in this retrospective cohort study. We analyzed the prognostic factors, including serum N‐telopeptide of type I collagen (NTX) levels, as bone metabolism markers. Results The median overall survival (OS) time was 11.5 months. Child–Pugh grade A ( P = 0.004) and intrahepatic tumor stage (IHTS) T0–3 ( P = 0.010) correlated significantly with favorable OS. In 46 patients with grade A and T0–3, receiver operating characteristic curve analysis defined 16 nmol BCE/L serum NTX as the cut‐off level for median OS. Multivariate analysis identified baseline serum NTX <16 nmol BCE/L ( P = 0.045) as the only significant and independent determinant of OS. Conclusion Low baseline serum NTX level correlated with favorable outcome in bone metastatic HCC patients with Child–Pugh grade A and IHTS T0–3 treated with ZOL.